<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03806803</url>
  </required_header>
  <id_info>
    <org_study_id>Pro00087406</org_study_id>
    <nct_id>NCT03806803</nct_id>
  </id_info>
  <brief_title>Multicentre Blinded Comparison of Lyophilized Sterile Fecal Filtrate to Lyophilized Fecal Microbiota Transplant in Recurrent Clostridioides Difficile Infection</brief_title>
  <official_title>A Multicenter Double Blind Randomized Study Comparing the Efficacy of Lyophilized Sterile Fecal Filtrate to Lyophilized Fecal Microbiota Transplantation (FMT) in the Management of Recurrent Clostridioides Difficile Infection (CDI)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Alberta</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of British Columbia</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Calgary</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>McGill University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Alberta</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Fecal microbiota transplantation (FMT) is a treatment that restores the balance of gut&#xD;
      bacteria and is the most effective treatment for patients who suffer from recurrent&#xD;
      Clostridioides difficile infection (CDI) brought on by antibiotic use. Although highly&#xD;
      effective, we do not understand how FMT actually works.&#xD;
&#xD;
      Freeze-dried or lyophilized fecal microbiota transplant (LFMT) has been shown to be&#xD;
      effective. Recently, filtered fecal slurry, free of any live bacteria, has also been shown to&#xD;
      cure 5 such patients. The advantage of the filtered fecal slurry is that it may be safer to&#xD;
      patients as it does not contain any live bacteria. We have conducted a pilot study comparing&#xD;
      LFMT to lyophilized sterile fecal filtrate (LSFF) in 9 patients, and found that the success&#xD;
      rate of treatment was 80% vs 75% in these 2 groups.&#xD;
&#xD;
      Therefore we need to perform a larger multicenter study to compare LFMT to LSFF to determine&#xD;
      the success rate of curing these patients.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This prospective double blind randomized study will enroll 248 patients with recurrent&#xD;
      Clostridium difficile infection (RCDI) in a 1:1 ratio to receive either LFMT or LSFF by&#xD;
      capsules.&#xD;
&#xD;
      Patients will receive 15 capsules at week 0 and be assessed at weeks 1, 4, 8 and 24. Blood,&#xD;
      stool and urine samples will be collected. If the first treatment fails, patients will be&#xD;
      given open label LFMT from the same donor. If treatment fails again, FMT will be offered in&#xD;
      the form and route at the treating physician's discretion.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 21, 2019</start_date>
  <completion_date type="Anticipated">March 2023</completion_date>
  <primary_completion_date type="Anticipated">March 2023</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>double blind randomized</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>LFMT and LSFF appear identical. Randomization is performed by lab staff not involved in any aspect of treatment administration or care.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Resolution of RCDI</measure>
    <time_frame>8 weeks</time_frame>
    <description>Proportion of patients without RCDI</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Resolution of RCDI</measure>
    <time_frame>24 weeks</time_frame>
    <description>Proportion of patients with sustained cure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serious Adverse Events</measure>
    <time_frame>8 weeks</time_frame>
    <description>Mortality directly attributable to CDI or treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serious Adverse Events</measure>
    <time_frame>8 weeks</time_frame>
    <description>Infection directly attributable to treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Minor Adverse Events</measure>
    <time_frame>1 week</time_frame>
    <description>Nausea</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Minor Adverse Events</measure>
    <time_frame>1 week</time_frame>
    <description>Vomiting</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Minor Adverse Events</measure>
    <time_frame>1 week</time_frame>
    <description>Abdominal discomfort</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Difficulty swallowing capsules</measure>
    <time_frame>1 week</time_frame>
    <description>Reported by patients as ranging between none, moderate or severe</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fever</measure>
    <time_frame>1 week</time_frame>
    <description>Temperature of &gt;37.8C</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">248</enrollment>
  <condition>Clostridia Difficile Colitis</condition>
  <condition>Clostridium Difficile Diarrhea</condition>
  <arm_group>
    <arm_group_label>LFMT</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Lyophilized fecal microbiota transplant capsules</description>
  </arm_group>
  <arm_group>
    <arm_group_label>LSFF</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Lyophilized sterile fecal filtrate capsules</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Lyophilized fecal microbiota transplant</intervention_name>
    <description>15 capsules</description>
    <arm_group_label>LFMT</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Lyophilized sterile fecal filtrate</intervention_name>
    <description>15 capsules</description>
    <arm_group_label>LSFF</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  at least 3 episodes of recurrent CDI with each episode defined as 3 or more unformed&#xD;
             stools in 24 hours associated with positive Clostridium difficile test, each occurring&#xD;
             within 3 months of each other.&#xD;
&#xD;
          -  CDI infection under symptomatic control with 3 or fewer unformed stools in 24 hours&#xD;
             for at least 2 consecutive days prior to treatment&#xD;
&#xD;
          -  Ability to provide informed consent&#xD;
&#xD;
          -  Females and males must agree to effective contraception for the duration of the study&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Severe or fulminant colitis&#xD;
&#xD;
          -  Chronic diarrheal illnesses such as irritable bowel syndrome or inflammatory bowel&#xD;
             disease unless under control or in remission 3 months prior to enrollment.&#xD;
&#xD;
          -  Those taking or planning to take an investigational drug within 3 months of enrollment&#xD;
&#xD;
          -  Chemotherapy or radiation therapy&#xD;
&#xD;
          -  Oropharyngeal or significant esophageal dysphagia&#xD;
&#xD;
          -  Ileus or small bowel obstruction&#xD;
&#xD;
          -  Pregnant or planning to become pregnant within 3 months&#xD;
&#xD;
          -  Breastfeeding or planning to breastfeed during the trial&#xD;
&#xD;
          -  Active infection requiring antibiotics&#xD;
&#xD;
          -  Life expectancy &lt;6 months Those with history of total colectomy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dina Kao, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Alberta</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Dina Kao, MD</last_name>
    <phone>780 492 8307</phone>
    <email>dkao@ualberta.ca</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of Alberta Hospital</name>
      <address>
        <city>Edmonton</city>
        <state>Alberta</state>
        <zip>T6G 2X8</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dina Kao, MD</last_name>
      <phone>780 492 8307</phone>
      <email>dkao@ualberta.ca</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of British Columbia</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ted Steiner, MD</last_name>
      <phone>604-875-4111</phone>
      <phone_ext>68492</phone_ext>
      <email>tsteiner@mail.ubc.ca</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of British Columbia</name>
      <address>
        <city>Victoria</city>
        <state>British Columbia</state>
        <zip>V8R 1J8</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Andrei Musaji, MD</last_name>
      <phone>250-519-7700</phone>
      <phone_ext>12939</phone_ext>
      <email>andrei.musaji@VIHA.ca</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Mcgill University</name>
      <address>
        <city>Montr√©al</city>
        <state>Quebec</state>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Vivian Loo, MD</last_name>
      <phone>514-934-1934</phone>
      <phone_ext>42818</phone_ext>
      <email>vivan.loo@mcgill.ca</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Of Calgary</name>
      <address>
        <city>Calgary</city>
        <zip>T2N 2T9</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Thomas Louie, MD</last_name>
      <phone>403-944-2038</phone>
      <email>thomas.louie@albertahealthservices.ca</email>
    </contact>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>January 14, 2019</study_first_submitted>
  <study_first_submitted_qc>January 14, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">January 16, 2019</study_first_posted>
  <last_update_submitted>October 19, 2021</last_update_submitted>
  <last_update_submitted_qc>October 19, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 27, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Clostridium Infections</mesh_term>
    <mesh_term>Diarrhea</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

